

April 8, 2025

AdvanCell proudly announces \$18M in Federal Funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate Cancer with Targeted Alpha Therapy’

One out of eight men develops prostate cancer. With the support from the Medical Research Future Fund Frontiers Initiative, the goal of the research team led by AdvanCell is to transform the clinical management of metastatic prostate cancer by leveraging world-leading therapeutic radiopharmaceutical technology paired with a deep understanding of cellular biology to improve the lives of patients with prostate cancer.

The research program is enabled by AdvanCell’s proprietary (Lead-212) ^{212}Pb alpha isotope production technology along with the delivery of a first-in-field clinical trial program and integrated biomarker study to accelerate the translation of ^{212}Pb -based Targeted Alpha Therapies, one of the most exciting breakthroughs in cancer treatment.

Dr. Anna Karmann MD PhD, AdvanCell Chief Medical Officer said

“On behalf of all Co-Investigators, I would like to thank the Australian Government and MRFF Frontiers Initiative committee for this prestigious award.

Targeted Alpha Therapies are among the most promising in oncology. We believe this MRFF-funded research can be practice-changing and have a lasting positive impact on the lives of patients with prostate cancer. We highly value the support and opportunity this funding provides to fast-track translation and accelerate the development of novel targeted alpha combination therapies.”

AdvanCell is collaborating with world-leading experts in Australia and globally, underpinning the transformative nature of the important clinical research. The team includes internationally renowned physician scientists Prof. Louise Emmett (St Vincent’s Hospital, Sydney) and Prof. Shahneen Sandhu (Peter MacCallum Cancer Centre, Melbourne). Scientific investigators include Prof. Richard Payne (The University of Sydney), Prof. Matt Trau, Dr. Alain Wuethrich, Kevin Koo (The University of Queensland), Dr. Scott Lovell (University of Bath), Dr. Thomas Kryza, Dr. Simon Puttick (AdvanCell) and A/Prof. Serigne Lo (Melanoma Institute Australia).

Prof. Stephen Rose, Head of Translational Medicine and Clinical Science at AdvanCell and grant PI, highlighted the importance of the MRFF funding, supporting Australian innovation to drive establishment of sovereign manufacturing capabilities to accelerate clinical translation of ^{212}Pb -Targeted Alpha Therapy.